Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Plus Therapeutics, Inc. PSTV
$4.12
-$0.52 (-12.71%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
12092651.00000000
-
week52high
18.00
-
week52low
3.15
-
Revenue
224000
-
P/E TTM
-7
-
Beta
0.39446300
-
EPS
-10.15000000
-
Last Dividend
0.00000000
-
Next Earnings Date
19 июл 2023 г. в 14:00
Описание компании
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 22 июл 2022 г. |
| HC Wainwright & Co. | Buy | 11 февр 2021 г. | |
| Ladenburg Thalmann | Buy | 25 янв 2021 г. | |
| Maxim Group | Buy | 16 окт 2020 г. | |
| Maxim Group | Hold | Buy | 15 авг 2018 г. |
| JonesTrading | Buy | 07 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lenk Robert P | D | 8500 | 1500 | 30 дек 2022 г. |
| HEDRICK MARC H | A | 33580 | 5000 | 15 июн 2022 г. |
| Clowes Howard | A | 18000 | 15000 | 02 июн 2022 г. |
| Petersen Greg | A | 62500 | 30000 | 17 мая 2022 г. |
| HEDRICK MARC H | A | 28580 | 2500 | 26 апр 2022 г. |
| HEDRICK MARC H | A | 26080 | 5000 | 26 апр 2022 г. |
| Sims Andrew John Hugh MacIntyre | A | 12230 | 3000 | 26 апр 2022 г. |
| Sims Andrew John Hugh MacIntyre | A | 9230 | 2000 | 01 мар 2022 г. |
| LaFrance Norman D. | A | 120000 | 120000 | 11 ноя 2021 г. |
| Sims Andrew John Hugh MacIntyre | A | 7230 | 1000 | 02 ноя 2021 г. |
Новостная лента
Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript
Seeking Alpha
20 апр 2023 г. в 22:30
Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript.
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
20 апр 2023 г. в 19:01
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference
GlobeNewsWire
18 апр 2023 г. в 16:15
AUSTIN, Texas, April 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Norman LaFrance, M.D., Chief Medical Officer and Senior Vice President, will participate as a panel presenter at the Canaccord Genuity Horizons in Oncology Virtual Conference.
Plus Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on April 20, 2023
GlobeNewsWire
12 апр 2023 г. в 07:00
AUSTIN, Texas, April 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report first quarter 2023 financial results on Thursday, April 20, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
Plus Therapeutics, Inc. (PSTV) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 февр 2023 г. в 23:07
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants Marc Hedrick - President and Chief Executive Officer Norman LaFrance - Chief Medical Officer Andrew Sims - Chief Financial Officer Conference Call Participants Justin Walsh - Jones Trading Edward Woo - Ascendiant Capital Sean Lee - HC Wainwright Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Fourth Quarter and Full Year 2022 Results Conference Call.